Table 2. Results from the Final Structural Model.

	β	p	95% CI	p Value
Internalizing 6-Month
ON Internalizing Baseline	.51	.60	.37, .83	.000
ON Treatment Condition	−2.47	−.15	−.29, -.02	.023
WITH Social 6-Month	11.55	.67	.58, .77	.000
ON Social Baseline	−.12	−.06	−.32, .21	.688
Social 6-Month
ON Social Baseline	.34	.41	.13, .68	.003
ON Treatment Condition	−.87	−.14	−.27, −.01	.042
ON Internalizing Baseline	.05	.16	−.06, .39	.161
Internalizing 12-Month
ON Internalizing 6−Month	.66	.60	.39, .80	.000
ON Internalizing Baseline	.11	.12	−.04, .27	.139
ON Treatment Condition	−1.97	−.11	−.22, −.01	.047
WITH Social 12-Month	7.20	.55	.40, .71	.000
ON Social 6-Month	.18	.06	−.11, .24	.492
Social 12-Month
ON Social 6-Month	.46	.49	.26, .72	.000
ON Social Baseline	.16	.19	.03, .36	.022
ON Treatment Condition	−.11	−.02	−.15, .11	.776
ON Internalizing 6-Month	.03	.08	−.17, .32	.531
Internalizing 18-Month
ON Internalizing 12-Month	.35	.38	.10, .65	.007
ON Internalizing 6-Month	.52	.50	.29, .72	.000
ON Treatment Condition	−.01	−.01	−.11, .11	.988
WITH Social 18-Month	4.39	.50	.37, .64	.000
ON Social 12-Month	.01	.01	−.15, .16	.950
Social 18-Month
ON Social 12-Month	.34	.35	.12, .57	.003
ON Social 6-Month	.30	.33	.15, .50	.000
ON Treatment Condition	−.22	−.04	−.16, .09	.543
ON Internalizing 12-Month	.07	.22	.02, .42	.032
Internalizing 24-Month
ON Internalizing 18-Month	.76	.77	.59, .94	.000
ON Internalizing 12-Month	.15	.17	.01, .33	.042
ON Treatment Condition	−.13	−.01	−.12, .11	.889
WITH Social 24-Month	6.69	.61	.49, .72	.000
ON Social 18-Month	−.41	−.14	−.32, .03	.103
Social 24-Month
ON Social 18-Month	.28	.26	.01, .51	.048
ON Social 12-Month	.34	.32	.13, .52	.001
ON Treatment Condition	−.24	−.04	−.17, .10	.577
ON Internalizing 18-Month	.07	.19	−.002, .38	.052